Wall Street Zen Upgrades Supernus Pharmaceuticals to 'Strong-Buy'

Analysts cite positive outlook for the specialty pharmaceutical company's CNS therapies.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Supernus Pharmaceuticals (NASDAQ:SUPN) has been upgraded by research analysts at Wall Street Zen from a 'buy' rating to a 'strong-buy' rating in a new research report. The report highlights the company's focus on developing and commercializing central nervous system (CNS) therapies, including its marketed portfolio of extended-release antiepileptic medications and a recently approved ADHD treatment.

Why it matters

Supernus Pharmaceuticals is a specialty pharmaceutical company that has built a reputation for innovative CNS therapies. The upgrade from Wall Street Zen signals increased optimism about the company's growth prospects and its ability to deliver value to shareholders through its product pipeline and commercial execution.

The details

The Wall Street Zen report cited several factors contributing to the 'strong-buy' rating, including positive analyst commentary from other firms and the company's track record of successfully bringing new CNS treatments to market. Supernus has focused on developing extended-release formulations of existing medications to improve patient outcomes, and its recently approved ADHD drug Qelbree has also generated excitement among investors.

  • The research report was issued on Saturday, March 2, 2026.
  • Supernus Pharmaceuticals' stock price has risen steadily over the past year, up from around $50 per share to the current level of $62.17.

The players

Supernus Pharmaceuticals

A specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies, including extended-release antiepileptic medications and a recently approved ADHD treatment.

Wall Street Zen

A research firm that provides analysis and investment recommendations to clients.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The upgrade of Supernus Pharmaceuticals to a 'strong-buy' rating by Wall Street Zen reflects the firm's confidence in the company's ability to continue delivering innovative CNS therapies that address unmet medical needs and drive shareholder value. As Supernus navigates the competitive pharmaceutical landscape, its focus on extended-release formulations and new treatment approvals appears to be resonating with analysts and investors alike.